Agaplesion Diakonieklinikum Rotenburg

Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases (2020) Laakmann E, Witzel I, Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mobus V, et al. Conference contribution Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry - comparison of three different prognostic scores (2020) Riecke K, Mueller , Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mundhenke C, et al. Conference contribution Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases (2020) Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, Möbus V, et al. Journal article Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry: Comparison of three different (2020) Riecke K, Mueller V, Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mundhenke C, et al. Conference contribution Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients (2018) Roellig C, Kramer M, Gabrecht M, Haenel MH, Herbst R, Kaiser U, Schmitz N, et al. Journal article Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry (2018) Witzel I, Laakmann E, Weide R, Neunhoeffer T, Park-Simon TJ, Schmidt M, Fasching P, et al. Journal article Characteristics and healthcare situation of adult patients with tuberous sclerosis complex in German epilepsy centers (2018) Hamer H, Pfaefflin M, Baier H, Boesebeck F, Franz M, Holtkamp M, Kurlemann G, et al. Journal article DICER1 mutation-positive Giant Botryoid Fibroepithelial polyp of the urinary bladder mimicking embryonal rhabdomyosarcoma (2018) Eckstein M, Agaimy A, Woenckhaus J, Winter A, Bittmann I, Janzen J, Bertz S, et al. Journal article Quo vadis DGPRÄC: associated members' goals for the future (2017) Kolbenschlag J, Paprottka F, Wagner J, Goertz O, Liebau J, Daigeler A, Horch RE, et al. Journal article Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial (2015) Rollig C, Serve H, Huettmann A, Noppeney R, Mueller-Tidow C, Krug U, Baldus CD, et al. Journal article